fda stance on compounded semaglutide The End of Semaglutide: Why the FDA's Decision Matters for Patients and Pharmacies - Seattle Plastic Surgery FDA crackdown on off-brand Ozempic

SUSTAIN 3 specifically compared semaglutide added to metformin (with or without sulfonylurea) against exenatide extended-release (another GLP-1 RA) with the same background therapy

When blood glucose rises after eating, GLP-1 binds to receptors on pancreatic beta cells

If coverage is denied, we can still provide low-cost options through compounding pharmacies

It is important to note that these benefits are based on trial data

This proactive approach ensures the therapy remains effective and minimizes complications

For weight management, inadequate response (less than 5% weight loss after several months at maintenance dose) may warrant reassessment of the treatment approach